These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9572544)

  • 61. Iris vasculopathy in galactose-fed rats.
    Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF
    Exp Eye Res; 1999 Feb; 68(2):211-21. PubMed ID: 10068486
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat.
    Meyer WR; Doyle MB; Grifo JA; Lipetz KJ; Oates PJ; DeCherney AH; Diamond MP
    Am J Obstet Gynecol; 1992 Dec; 167(6):1837-43. PubMed ID: 1471707
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.
    Wang X; Yu F; Zheng WQ
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):294-303. PubMed ID: 31389594
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose.
    Yasunari K; Kohno M; Kano H; Yokokawa K; Horio T; Yoshikawa J
    Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2207-12. PubMed ID: 7489244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Endothelial changes in galactose-fed dogs.
    Neuenschwander H; Julia C; Wyman M; Kador PF
    Curr Eye Res; 1995 Apr; 14(4):319-22. PubMed ID: 7606918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retinal vessel changes in galactose-fed dogs.
    Kobayashi T; Kubo E; Takahashi Y; Kasahara T; Yonezawa H; Akagi Y
    Arch Ophthalmol; 1998 Jun; 116(6):785-9. PubMed ID: 9639449
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
    Ikeda T; Iwata K; Tanaka Y
    Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Galactosemic neuropathy in transgenic mice for human aldose reductase.
    Yagihashi S; Yamagishi S; Wada R; Sugimoto K; Baba M; Wong HG; Fujimoto J; Nishimura C; Kokai Y
    Diabetes; 1996 Jan; 45(1):56-9. PubMed ID: 8522060
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats.
    Hosotani H; Ohashi Y; Kinoshita S; Matsumoto T; Awata T
    Curr Eye Res; 1996 Oct; 15(10):1005-7. PubMed ID: 8921238
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
    Matsuoka K; Sakamoto N; Akanuma Y; Hotta N; Shichiri M; Toyota T; Oka Y; Kawamori R; Shigeta Y;
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S263-8. PubMed ID: 17599629
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of seven days of galactose feeding and aldose reductase inhibition on mast cells and vessel morphometry in rat sciatic nerve.
    Brett FM; Kalichman MW; Calcutt NA; Mizisin AP
    J Neurol Sci; 1996 Sep; 141(1-2):6-12. PubMed ID: 8880685
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of polyol pathway in nonenzymatic glycation.
    Hamada Y; Araki N; Horiuchi S; Hotta N
    Nephrol Dial Transplant; 1996; 11 Suppl 5():95-8. PubMed ID: 9044317
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative analysis of retinal vessel changes in galactose-fed dogs.
    Takahashi Y; Augustin W; Wyman M; Kador PF
    J Ocul Pharmacol; 1993; 9(3):257-69. PubMed ID: 8228533
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via KvĪ²1.1 (AKR6A8) subunit of voltage-gated potassium channel.
    Tur J; Badole SL; Cheng F; Das A; Kukreja RC; Tipparaju SM
    Mol Cell Biochem; 2017 Dec; 436(1-2):71-78. PubMed ID: 28585087
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro.
    Sturm K; Levstik L; Demopoulos VJ; Kristl A
    Eur J Pharm Sci; 2006 May; 28(1-2):128-33. PubMed ID: 16497491
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Administration of an aldose reductase inhibitor, ONO-2235, to streptozotocin-diabetic mice restores reductions of DRG neuronal attachment to extracellular matrix proteins in vitro.
    Sango K; Horie H; Inoue S
    Neurosci Lett; 1999 Mar; 263(2-3):157-60. PubMed ID: 10213159
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevention of nerve edema and increased blood-nerve barrier permeability-surface area product in galactosemic rats by aldose reductase or thromboxane synthetase inhibitors.
    Wadhwani KC; Caspers-Velu LE; Murphy VA; Smith QR; Kador PF; Rapoport SI
    Diabetes; 1989 Nov; 38(11):1469-77. PubMed ID: 2559867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia.
    Engerman RL; Kern TS
    Arch Ophthalmol; 1995 Mar; 113(3):355-8. PubMed ID: 7887850
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112.
    Hosotani H; Ohashi Y; Yamada M; Tsubota K
    Am J Ophthalmol; 1995 Mar; 119(3):288-94. PubMed ID: 7872388
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Improved method of epalrestat synthesis].
    Sheng R; Liu T; Hu YZ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Aug; 32(4):356-8. PubMed ID: 12970944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.